Drugs / fetal MSCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06435897 | May 2024 → Jul 2027 expected | autoimmune disease | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fetal MSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06435897 ↗ |
| Known as | fMSCs | “fetal tissue-derived clonal MSCs (fMSCs) have extended expansion potential and express rich levels of various growth factors.” NCT06435897 ↗ |
| Route | Intravenous | “via IV” NCT06435897 ↗ |